Lighting up proteins with Immuno-SABER
A simple and robust DNA-based signal amplification method to simultaneously visualize multiple proteins in tissues has the potential to accelerate many large-scale protein mapping and biomarker discovery projects
Credit: Wyss Institute at Harvard University
(BOSTON) — To better understand how tissues and organs develop, fail to function, and regenerate over time, researchers would like to visualize their constituent cells’ repertoires of molecules within 3D space. Ambitious efforts like the “Human BioMolecular Atlas Program”, the “Human Cell Atlas Project”, and several brain atlas projects are underway to map the presence and abundance of many proteins – the products of gene expression – in organs and tissues of the human body at the scale of single cells. However, existing imaging methods are typically limited in various aspects of their performance, their accessibility to researchers, or both.
As reported in Nature Biotechnology, a team led by Peng Yin, Ph.D., at Harvard’s Wyss Institute for Biological Engineering and Harvard Medical School (HMS) has now filled this void with a new DNA-nanotechnology-based approach called Immuno-SABER, short for “Immunostaining with Signal Amplification By Exchange Reaction.” The method combines the protein targeting specificity of commonly available antibodies with a DNA-based signal-amplification strategy that enables the highly multiplexed visualization of many proteins in the same sample with pre-programmable and tunable fluorescence signals at each target site. The team has validated their method in a broad range of cell and tissue preparations.
“We demonstrated that Immuno-SABER provides the capability to independently tune the signal intensity for individual protein targets 5 to 180-fold, with multiplexing capability to allow the simultaneous detection of many proteins. Together with its speed, relative ease of use and low costs, this technique has the potential to fast-forward ongoing large-scale protein-mapping studies and biomarker discovery efforts across many tissues and diseases,” said Peng Yin who is a Wyss Institute Core Faculty member.
Based on his group’s advances in harnessing DNA nanotechnology-driven barcoding and signal amplification technologies, Yin recently was recently also selected as an awardee of the Human BioMolecular Atlas Program (HuBMAP) and an awardee of the Human Cell Atlas Project. He also is co-leader of the Wyss Institute’s Molecular Robotics Initiative, and Professor of Systems Biology at HMS.
Antibodies are the most common detection reagents for proteins both in research and clinical settings. They are typically tagged with fluorescent stains to make them detectable by microscopy. However, conventional antibody staining methods typically allow only a maximum of five different stains to be used simultaneously, and target proteins can differ significantly in their abundances, making it difficult to distinguish rare protein targets with high sensitivity from the background fluorescence that many tissues display.
Immuno-SABER utilizes the “Primer Exchange Reaction” (PER) method previously reported by Yin’s group to synthesize long concatemers of short DNA primer sequences with the help of a catalytic DNA hairpin structure. The PER-generated concatemers are attached via short handle sequences to DNA-barcodes on antibodies that bind to target proteins in fixed cell and tissue samples with high specificity. At the target site, SABER concatemers provide a scaffold with multiple binding sites for complementary fluorescent oligonucleotides (“imagers”), and thus a means to amplify the signal emanating from each protein target.
“By barcoding antibodies with unique short DNA sequences and applying Immuno-SABER, we can simultaneously visualize multiple protein targets on the same sample and with high specificity. This essentially opens up a way to analyze the protein variety present in tissues in a robust and multiplexed fashion,” said co-first and co-corresponding author Sinem Saka, Ph.D., who works as a Postdoctoral Fellow on Yin’s team.
The team significantly boosted the multiplexing potential of their Immuno-SABER approach by coupling it with their previously developed “DNA-Exchange” technique. In DNA-Exchange, imagers that mark one set of target proteins are washed off and replaced by another set of imagers marking a different group of target proteins and this can be repeated multiple times.
Previously developed methods for highly multiplexed protein detection that work by repeating some of their key steps at different protein targets tend to suffer from suboptimal sensitivities, or take considerable time (low throughput) and finesse to execute. “Exchange-SABER” provides high sensitivity with one single step of staining and amplification, and high multiplexing and throughput with multiple fast imager exchange steps,” said co-first author Yu Wang, who is a graduate student on Yin’s team. “As proof-of-concept, we visualized 10 different proteins in cryosections of the mouse retina.”
Wang was co-mentored by co-author George Church, Ph.D., who is a Core Faculty member at the Wyss Institute and Professor of Genetics at HMS and of Health Sciences and Technology at Harvard University and the Massachusetts Institute of Technology (MIT).
Another key facet of Immuno-SABER facilitating the parallel detection of many proteins at a time is its ability to tune signal strength. The team achieved this by assembling more complex branched structures from PER-generated concatemers that contain higher numbers of binding sites for fluorescent imagers. “Programming the complexity of PER-based concatemer structures allows us to tune the signal strength to the abundance of particular proteins. We can at the same time visualize rare proteins with branched SABER products that enable higher signal amplification, and abundant proteins with linear SABER products,” said Saka. In their study, the team combined linear and branched SABER concatemers to, for example, simultaneously visualize six protein targets with different abundances and cellular locations in human tonsil samples.
Yin’s team’s existing suite of DNA nanotechnology-powered imaging technologies including DNA-PAINT and Discrete Molecular Imaging, have advanced the field of super-resolution microscopy, which allows researchers to study single molecules at their normal locations. To achieve similarly high resolution of proteins in more complex tissue environments the team combined Immuno-SABER with a method known as “Expansion Microscopy”, which was previously developed by co-author Edward Boyden, Ph.D., the Y. Eva Tan Professor in Neurotechnology at MIT. The expansion method swells fixed tissues artificially to larger volumes, which increases the separation distance between individual molecules and thus improves their effective resolution without the need for specialized instruments. “Combining Expansion Microscopy with Exchange-SABER simultaneously gives us the high-multiplexing, -throughput, and -resolution capabilities needed to move efforts such as building molecular atlases for the human body more effectively forward,” said Wang.
“Peng Yin’s team again demonstrates how they can program engineered DNA molecules to carry out specific tasks like molecular robots, in this case allowing us to visualize simultaneously the location of numerous proteins within human cells and tissues with high resolution, which should greatly accelerate discovery of molecular mechanisms of biological control as well as new disease biomarkers,” said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS, the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at Harvard’s John A. Paulson School of Engineering and Applied Sciences (SEAS).
By Benjamin Boettner
Additional authors on the study are past and present members of Yin’s team, including Wyss Technology Development Fellow Jocelyn Kishi, Ph.D., Allen Zhu, Yitian Zeng, Wenxin Xie, Brian Beliveau, Ph.D., a former Postdoc working with Yin and now Assistant Professor at the University of Washington’s Department of Genome Sciences in Seattle, Siyuan Yin, Millicent Lin; Sylvain Lapan, Ph.D., Koray K?rl?, Ph.D., Clarence Yapp, Ph.D., Marcelo Cicconet, Ph.D., Pascal Kaeser, M.D., Associate Professor, at HMS, German Pihan, M.D., Harvard Medical Faculty Physician at Beth Israel Deaconess Medical Center, Boston. The study was funded by Harvard’s Wyss Institute for Biologically Inspired Engineering, the National Institutes of Health, Office of Naval Research, National Science Foundation, Harvard Medical School’s Dean Initiative, and Howard Hughes Medical Institute, as well as fellowships from the Damon Runyon Cancer Research Foundation, Human Frontier Science Program, and EMBO.
Wyss Institute for Biologically Inspired Engineering at Harvard University
Benjamin Boettner, [email protected], +1 617-432-8232
The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature’s design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard’s Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.
Harvard Medical School has more than 11,000 faculty working in 10 academic departments located at the School’s Boston campus or in hospital-based clinical departments at 15 Harvard-affiliated teaching hospitals and research institutes: Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Cambridge Health Alliance, Dana-Farber Cancer Institute, Harvard Pilgrim Health Care Institute, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children’s Center, Massachusetts Eye and Ear/Schepens Eye Research Institute, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Spaulding Rehabilitation Network and VA Boston Healthcare System.